MDDD, a 4,9-diazapyrenium derivative, is selectively toxic to glioma cells by inducing growth arrest at G0/G1 independently of p53

Investigational New Drugs

Volumn 24, Issue 6, 2006, Pages 489-498

  Yu, De Hua ^a   MacDonald, James ^a   Josephs, Steve ^a   Liu, Qi ^a   Nguy, Vivian ^a   Tor, Yitzhak ^b   Wong Staal, Flossie ^a   Li, Qi Xiang ^a  

^a Immusol Inc   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

4 methyl 2,7 diamino 5,10 diphenyl 4,9 diazapyrenium chloride (MDDD); Apoptosis; Cell cycle; Glioma; Selective cytoxicity

Indexed keywords

4 METHYL 2,7 DIAMINO 5,10 DIPHENYL 4,9 DIAZAPYRENIUM CHLORIDE; 4,9 DIAZAPYRENIUM DERIVATIVE; ANTINEOPLASTIC AGENT; PROTEIN P21; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CLONOGENESIS; CONTROLLED STUDY; DNA DAMAGE; DRUG STRUCTURE; GLIOMA CELL; HUMAN; HUMAN CELL; IC 50; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DNA; DNA DAMAGE; G0 PHASE; G1 PHASE; GLIOMA; HUMANS; INHIBITORY CONCENTRATION 50; INTERCALATING AGENTS; PYRIDINIUM COMPOUNDS; RATS; RNA INTERFERENCE; TUMOR STEM CELL ASSAY; TUMOR STEM CELLS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33747655160     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-006-7590-1     Document Type: Article

References (19)

1. Greenlee RT, Murray T, Bolden S, Wingo PA (2000) Cancer statistics, 2000. CA Cancer J Clin 50:7-33
2. CBTRUS Central Brain Tumor Registry of the United States, Primary Brain Tumors in the United States Statistical Report 1995-1999 edition, pp. 2002
3. Pendergrass TW, Milstein JM, Geyer JR, Mulne AF, Kosnik EJ, Morris JD, Heideman RL, Ruymann FB, Stuntz JT, Bleyer WA (1987) Eight drugs in one day chemotherapy for brain tumors: Experience in 107 children and rationale for preradiation chemotherapy. J Clin Oncol 5:1221-1231
4. Parney IF, Chang SM (2003) Current chemotherapy for glioblastoma. Cancer J 9:149-156
5. Hirose Y, Berger MS, Pieper RO (2001) p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res 61:1957-1963
6. Piantanida I, Palm BS, Zinic M, Schneider H-J (2001) A new 4,9-diazapyrenium intercalator for single- and double-stranded nuclei acids: distinct differences from related diazapyrenium compounds and ethidium bromide. J Chem Soc Perkin Trans 2:1808-1816
7. Steiner-Biocic I, Glavas-Obrovac L, Karner I, Piantanida I, Zinic M, Pavelic K, Pavelic J (1996) 4,9-diazapyrenium dications induce apoptosis in human tumor cells. Anticancer Res 16:3705-3708
8. Ronic S, Glavas-Obrovac L, Karner I, Piantanida I, Zinic M, Pavelic K (2000) In vitro Cytotoxicity of three 4,9-diazapyrenium hydrogensulfate derivatives on different human tumor cell lines. Chemotherapy 46:143-149
9. Claassen G, Ke N, Yu DH, Chatterton JE, Hu X, Albers A, Nguy V, Chionis J, Truong T, Meyhack B, Wong-Staal F, Li QX (2004) Comprehensive assessment of cell growth properties affected by various agents using an integrated and non-subjective approach. Preclinica 2:435-439
10. Brummelkamp TR, Bernards R, Agami R (2002) Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2:243-247
11. Tiscornia G, Singer O, Ikawa M, Verma IM (2003) A general method for gene knockdown in mice by using lentiviral vectors expressing small interfering RNA. Proc Natl Acad Sci USA 100:1844-1848
12. Ke N, Albers A, Claassen G, Yu DH, Chatterton JE, Hu X, Meyhack B, Wong-Staal F, Li QX (2004) One-week 96-well soft agar growth assay for cancer target validation. Biotechniques 36:826-828, 830, 832-823
13. Ke N, Claassen G, Yu DH, Albers A, Fan W, Tan P, Grifman M, Hu X, Defife K, Nguy V, Meyhack B, Brachat A, Wong-Staal F, Li QX (2004) Nuclear hormone receptor NR4A2 is involved in cell transformation and apoptosis. Cancer Res 64:8208-8212
14. Fiebig HH, Maier A, Burger AM (2004) Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery. Eur J Cancer 40:802-820
15. Weiss RH (2003) p21Waf1/Cip1 as a therapeutic target in breast and other cancers. Cancer Cell 4:425-429
16. Yu DH, Chatterton JE, Ke N, Nguy V, Bliesath JR, Hu X, Meyhack B, Wong-Staal F, Li QX (2005) A 96 well surrogate survival assay coupled with a special RNAi vector strategy for cancer gene target identification and validation with enhanced signal/noise ratio. Assay Drug Dev Tech 3:401-411
17. Valtonen S, Timonen U, Toivanen P, Kalimo H, Kivipelto L, Heiskanen O, Unsgaard G, Kuurne T (1997) Interstitial chemothrepy with carmustine-loaded polymers for high-grade gliomas: A randomized double-blinds. Neurosurgery 41:44-49
18. Chen Y, Sanchez Y (2004) Chk1 in the DNA damage response: conserved roles from yeasts to mammals. DNA Repair (Amst) 3:1025-1032
19. Kong XB, Rubin L, Chen LI, Ciszewska G, Watanabe KA, Tong WP, Sirotnak FM, Chou TC (1992) Topoisomerase II-mediated DNA cleavage activity and irreversibility of cleavable complex formation induced by DNA intercalator with alkylating capability. Mol Pharmacol 41:237-244